Universe Pharmaceuticals INC
Universe Pharmaceuticals INC is a Cayman Islands holding company headquartered in Ji'an, Jiangxi, China, that operates through subsidiaries in Hong Kong and mainland China. The company manufactures, markets, sells, and distributes traditional Chinese medicine derivative products, along with biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueManufactured and marketed products aimed at elderly health and age-related conditions.
Third-party biomedical pharmaceuticals distributed and sold through the company network.
Prepared Chinese medicine pieces sold through the company's pharmaceutical channels.
Medical devices and instruments distributed alongside the company's drug portfolio.
Supplement products sold to support general wellness and aging-related needs.
Products
Reported · share of revenue- Revenue From Sales of Selfmanufactured TCMD Products74.3 %
- Revenue From Sales of Thirdparty Products25.7 %
Source: 20-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells through pharmaceutical channels in China to end users and intermediaries that buy medicines, supplements, and medical instruments for retail or local distribution. Its product positioning is centered on older consumers and age-related wellness needs, while part of the assortment is sourced from third-party manufacturers and distributed through the company's sales network.
Buy traditional Chinese medicine derivative products designed for aging-related conditions and wellness.
Purchase pharmaceutical products and supplements for downstream resale to consumers.
Buy biomedical drugs, medical instruments, and TCM pieces for broader market coverage.
Purchase dietary supplements for general health and preventive use.
Strategy
The company's strategy is centered on building a pharmaceutical platform focused on elderly healthcare, age-related conditions, and adjacent wellness categories. It also seeks to broaden its asset base and product platform through acquisitions and by adding intellectual property assets, while maintaining a China-based distribution footprint.
Targets a distinct demand pool where aging-related conditions support specialized product positioning.
Acquisitions can broaden product scope and add assets that support the company's pharmaceutical platform.
A wider assortment reduces dependence on any single product class and supports distribution relationships.
National provincial coverage improves access to downstream buyers and supports scale in the domestic market.
Geography
Universe Pharmaceuticals is headquartered in Ji'an, Jiangxi, China and operates primarily in mainland China through its PRC subsidiary. The company states that its products are sold in 30 provinces of China, making domestic reach the key geographic feature of the business.
Risks
The business is exposed to Chinese pharmaceutical regulation, product quality and compliance requirements, and dependence on domestic distribution channels. It also faces integration and execution risk around acquisitions, as well as demand and reimbursement pressure typical of consumer-facing healthcare products in a competitive market.
- China pharmaceutical regulationImpact: HighLikelihood: High
Drug, medical device, and supplement sales depend on compliance with local rules and approvals.
Exposure: Mainland China operations
- Single-country concentrationImpact: HighLikelihood: High
Sales are primarily in China, so local demand, policy, or distribution disruptions have outsized impact.
Exposure: China
- Product quality and recall riskImpact: HighLikelihood: Medium
Manufacturing and distributing healthcare products creates exposure to quality failures and remediation costs.
Exposure: Manufactured and third-party products
- Acquisition execution riskImpact: MediumLikelihood: Medium
The company is pursuing asset additions that may not close or may not deliver expected strategic value.
Exposure: Intellectual property acquisition
Accounting
Judgemental itemsPharmaceutical and distribution sales may be recognized at different points depending on delivery terms.
Impact: Affects quarterly revenue comparability and cut-off judgments
PRC subsidiaries participate in mandated social security and housing fund plans.
Impact: Affects operating expenses and accrued liabilities
The group operates across China, Hong Kong, and U.S.-reported financial statements.
Impact: Can affect cash flow, equity, and comprehensive income
Six-month results may not reflect full-year seasonality or product demand patterns.
Impact: Limits comparability between interim and annual periods
Similar listed companies
Publicly listed companies with a comparable business focus.
China Pharma Holdings, Inc
CPHI · Pharmaceutical Preparations
China SXT Pharmaceuticals, Inc.
SXTC · Pharmaceutical Preparations
Zhongchao Inc.
ZCMD · Services-Educational Services
Kun Peng International Ltd.
KPEA · Services-Educational Services
Antiaging Quantum Living Inc.
AAQL · Services-Direct Mail Advertising Services
BGM Group Ltd.
BGM · Pharmaceutical Preparations
BGM Group Ltd is a Cayman Islands holding company with operating businesses primarily conducted through subsidiaries and variable interest entities in mainland China.
Last updated: 28/09/2026